切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2023, Vol. 19 ›› Issue (04) : 394 -402. doi: 10.3877/cma.j.issn.1673-5250.2023.04.004

专题论坛

上皮性卵巢癌"二元论模型"的分子生物学研究现状
陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建†()   
  1. 四川大学华西第二医院放射科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
    拜耳医药保健有限公司，广州　510030
  • 收稿日期:2023-04-01 修回日期:2023-07-07 出版日期:2023-08-01
  • 通信作者: 陈锡建

Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology

Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen†()   

  1. Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    Bayer Healthcare Company Limited, Guangzhou 510030, Guangdong Province, China
  • Received:2023-04-01 Revised:2023-07-07 Published:2023-08-01
  • Corresponding author: Xijian Chen
  • Supported by:
    Key Research & Development Project of Department of Science and Technology in Sichuan Province(2020YFS0050); Clinical Research Fund of West China Second University Hospital, Sichuan University(KL007)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.

Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen. Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 394-402.

上皮性卵巢癌(EOC)是导致患者死亡率最高的妇科肿瘤。EOC具有多种病理学类型，根据发病机制及"二元论模型(dualistic model)"可将其分为Ⅰ、Ⅱ型EOC。由于Ⅰ、Ⅱ型EOC具有不同发病机制、前驱病变及基因遗传学改变等，因此在肿瘤化疗敏感度和患者预后方面，均具有完全不同的临床结局。"二元论模型"对EOC患者可进行精准分型，并且可进一步探究其相关信号通路，而这些均有助于临床医师对EOC的预防、诊疗等采取更有效的方案，从而明显改善EOC患者的生存质量。笔者拟针对EOC"二元论模型"的提出、临床特点、分子遗传学特征，以及以"二元论模型"对EOC患者的早期诊断、预防及治疗策略等的最新研究现状进行阐述。

关键词: 卵巢肿瘤, 上皮性卵巢癌, 低级别浆液性卵巢癌, 二元论模型, 分子生物学, 精准医学, 女(雌)性

Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological tumors. EOC has multiple pathological types, which can be divided into type Ⅰ and Ⅱ based on the pathogenesis and " dualistic model". Due to their different pathogeneses, precursors and molecular genetics, type Ⅰ and Ⅱ EOC have a different chemotherapy protocol and prognosis. Due to differences in pathogenesis, precursor lesions, and genetic alterations between type Ⅰ and type Ⅱ EOC, there are significant differences in tumor chemotherapy sensitivity and patients prognosis, resulting in completely different clinical outcomes. The accurate classification of EOC and the further exploration of the related molecular pathways by the " dualistic model" can help clinicians adopt more effective prevention, diagnosis and treatment, thus significantly improving the quality of life of EOC patients. The author aims to elaborate on the proposal of the " dualistic model" for EOC, its clinical characteristics, molecular genetic features, and the latest research status of early diagnosis, prevention, and treatment strategies based on the " dualistic model" for EOC patients.

Key words: Ovarian neoplasms, Epithelial ovarian cancer, Low-grade serous ovarian cancer, Dualistic model, Molecular biology, Precision medicine, Female
[1]
李俊东，刘韬，万挺．上皮性卵巢癌规范化维持治疗专家共识[J]. 今日药学，2023, 33(4): 241-247.
[2]
Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer [J]. Lancet, 2019, 393(10177): 1240-1253. DOI: 10.1016/S0140-6736(18)32552-2.
[3]
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review [J]. Semin Oncol Nurs, 2019, 35(2): 151-156. DOI: 10.1016/j.soncn.2019.02.001.
[4]
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine [J]. CA Cancer J Clin，2019，69(4): 280-304. DOI: 10.3322/caac.21559.
[5]
Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma [J]. Am J Pathol, 2002, 160(4): 1223-1228. DOI: 10.1016/s0002-9440(10)62549-7.
[6]
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system [J]. Am J Surg Pathol, 2004, 28(4): 496-504. DOI: 10.1097/00000478-200404000-00009.
[7]
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis [J]. Am J Pathol, 2004, 164(5): 1511-1518. DOI: 10.1016/s0002-9440(10)63708-x.
[8]
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018 [J]. CA Cancer J Clin, 2018, 68(4): 284-296. DOI: 10.3322/caac.21456.
[9]
中国抗癌协会妇科肿瘤专业委员会. 卵巢上皮性癌一线化疗中国专家共识[J]. 实用妇产科杂志，2022, 38(8): 582-588. DOI: 1003-6946(2022)08-0582-07.
[10]
Hollis L. Molecular characteristics and clinical behaviour of epithelial ovarian cancers [J]. Cancer Lett, 2023, 28: 555. DOI: 10.1016/j.canlet.2023.216057.
[11]
Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science [J]. Gynecol Oncol, 2020, 156(3): 715-725. DOI: 10.1016/j.ygyno.2019.12.033.
[12]
Babaier A, Mal H, Alselwi W, et al. Low-grade serous carcinoma of the ovary: the current status [J]. Diagnostics (Basel), 2022, 12(2): 458. DOI: 10.3390/diagnostics12020458.
[13]
Wang Y, Hong S, Mu J, et al. Tubal origin of " ovarian" low-grade serous carcinoma: a gene expression profile study [J]. J Oncol, 2019, 2019: 8659754. DOI: 10.1155/2019/8659754.
[14]
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma [J]. Clin Cancer Res, 2022, 28(20): 4456-4465. DOI: 10.1158/1078-0432.CCR-21-4183.
[15]
Gershenson DM, Sun CC, Westin SN, et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes [J]. Gynecol Oncol, 2022, 165(3): 560-567. DOI: 10.1016/j.ygyno.2021.11.019.
[16]
ElNaggar A, Robins D, Baca Y, et al. Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy [J]. Gynecol Oncol, 2022, 10: S0090-8258(22)01850-9. DOI: 10.1016/j.ygyno.2022.09.022.
[17]
Cheasley D, Nigam A, Zethoven M, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities [J]. J Pathol, 2021, 253(1): 41-54. DOI：10.1002/path.5545.
[18]
中国医师协会妇产科医师分会妇科肿瘤专业委员会(学组)，马晓欣，向阳．卵巢子宫内膜样癌临床诊治中国专家共识(2023年版)[J].中国实用妇科与产科杂志，2023, 39(4): 445-451. DOI: 10.19538/j.fk2023040113.
[19]
Hollis RL, Thomson JP, Stanley B, et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome [J]. Nat Commun, 2020, 11(1): 4995. DOI: 10.1038/s41467-020-18819-5.
[20]
Cybulska P, Paula ADC, Tseng J, et al. Molecular profiling and molecular classification of endometrioid ovarian carcinomas [J]. Gynecol Oncol, 2019, 154(3): 516-523. DOI: 10.1016/j.ygyno.2019.07.012.
[21]
Pierson WE, Peters PN, Chang MT, et al. An integrated molecular profile of endometrioid ovarian cancer [J]. Gynecol Oncol, 2020, 157(1): 55-61. DOI: 10.1016/j.ygyno.2020.02.011.
[22]
Hollis RL, Stanley B, Thomson JP, et al. Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification [J]. NPJ Precis Oncol, 2021, 5(1): 47. DOI: 10.1038/s41698-021-00187-y.
[23]
Hollis RL, Stanley B, Iida Y, et al. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma [J]. Gynecol Oncol, 2019, 155(2): 318-323. DOI: 10.1016/j.ygyno.2019.09.001.
[24]
Zyla RE, Olkhov-Mitsel E, Amemiya Y, et al. CTNNB1 mutations and aberrant β-catenin expression in ovarian endometrioid carcinoma: correlation with patient outcome [J]. Am J Surg Pathol, 2021, 45(1): 68-76. DOI: 10.1097/PAS.0000000000001553.
[25]
中国医师协会妇产科医师分会妇科肿瘤学组，张国楠，向阳．卵巢透明细胞癌临床诊治中国专家共识(2022年版)[J].中国实用妇科与产科杂志，2022, 38(5): 9. DOI: 10.19538/j.fk2022050110.
[26]
Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective [J]. Int J Gynecol Cancer, 2021, 31(4): 605-616. DOI: 10.1136/ijgc-2020-001656.
[27]
Prat J. New insights into ovarian cancer pathology [J]. Ann Oncol, 2012, 23 (Suppl 10): x111-x117. DOI: 10.1093/annonc/mds300.
[28]
中国研究型医院学会腹膜后与盆底疾病专业委员会. 黏液性卵巢癌诊断与治疗中国专家共识(2021) [J]. 中国微创外科杂志，2021, 21(7): 577-588. DOI: 10.3969/j.issn.1009-6604.2021.07.001.
[29]
Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma [J]. N Engl J Med, 2019, 380(13): 1256-1266. DOI: 10.1056/NEJMra1813254.
[30]
Kato N, Kamataki A, Kurotaki H. Methylation profile of imprinted genes provides evidence for teratomatous origin of a subset of mucinous ovarian tumours [J]. J Pathol, 2021, 254(5): 567-574. DOI: 10.1002/path.5702.
[31]
Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma [J]. Nat Commun, 2019, 10(1): 3935. DOI: 10.1038/s41467-019-11862-x.
[32]
Meagher NS, Gorringe KL, Wakefield M, et al. Gene-expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes [J]. Clin Cancer Res, 2022, 28(24): 5383-5395. DOI: 10.1158/1078-0432.CCR-22-1206.
[33]
王虹桥，徐东东，刘冲，等. 卵巢恶性Brenner瘤多发转移死亡一例并文献复习 [J].国际生殖/计划生育杂志. 2021，40(3):202-215. DOI: 10.12280/gjszjk.20200502.
[34]
Kurman RJ, Ie-Ming Shih. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded [J].Am J Pathol, 2016, 186(4): 733-747. DOI: 10.1016/j.ajpath.2015.11.011.
[35]
Govindarajan M, Wohlmuth C, Waas M, et al. High-through put approaches for precision medicine in high-grade serous ovarian cancer [J]. J Hematol Oncol, 2020, 13(1): 134. DOI: 10.1186/s13045-020-00971-6.
[36]
Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints [J]. Int J Mol Sci, 2019, 20(4): 952. DOI: 10.3390/ijms20040952.
[37]
Hollis RL, Meynert AM, Michie CO, et al. Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification [J]. Clin Cancer Res, 2022, 28(16): 3546-3556. DOI: 10.1158/1078-0432.CCR-22-0368.
[38]
Millstein J, Budden T, Goode EL，et al. Prognostic gene expression signature for high-grade serous ovarian cancer [J]. Ann Oncol, 2020, 31(9): 1240-1250. DOI: 10.1016/j.annonc.2020.05.019.
[39]
Hollis RL, Croy I, Churchman M, et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma [J]. Br J Cancer, 2022, 127(6): 1034-1042. DOI: 10.1038/s41416-022-01874-8.
[40]
王桂业，陈琼，谢奇朋．血清人附睾蛋白4，糖链抗原125及卵巢恶性肿瘤风险算法在上皮性卵巢癌二元论分型中的应用价值[J].中国卫生检验杂志，2020, 30(2): 5.
[41]
中国抗癌协会妇科肿瘤专业委员会．卵巢恶性肿瘤诊断与治疗指南(2021) [J].中国癌症杂志，2021, 31(6): 490-500. DOI: 10.19401/j.cnki.1007-3639.2021.06.07.
[42]
王兴国，徐智阳，刘淑娟，等. 肿瘤标志物在卵巢癌诊断中的研究进展[J]. 中国癌症防治杂志，2022, 14(1): 111-116. DOI: 10.3969/j.issn.1674-5671.2022.01.19.
[43]
汤梓莹，邓明港，宇传华，等. 中国卵巢癌疾病负担现状及趋势分析[J]. 国际妇产科学杂志，2022, 49(2): 222-227. DOI: 10.12280/gjfckx.20211193.
[44]
苏梦婵，郑莹. 2022 NCCN遗传性/家族性卵巢癌风险评估与临床管理指南解读[J]. 实用妇产科杂志，2022, 38(7): 508-512. DOI: 1003-6946(2022)07-0508-05.
[45]
中国医院协会妇产医院分会妇科肿瘤专业学组，王建东，王玉东. 预防性输卵管切除术的中国专家共识(2021)[J]. 中国实用妇科与产科杂志，2021, 37(8): 826-831. DOI: 10.19538/j.fk2021080110.
[46]
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226. DOI: 10.6004/jnccn.2021.0007.
[47]
Monk BJ, Grisham RN, Banerjee S, et al. MILO/ENGOT-ov11: binimetinib versus physician′s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum [J]. J Clin Oncol, 2020, 38(32): 3753-3762. DOI: 10.1200/JCO.20.01164.
[48]
Gershenson DM, Miller A, Brady WE et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial [J]. Lancet, 2022, 399(10324): 541-553. DOI: 10.1016/S0140-6736(21)02175-9.
[1] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[2] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[3] 顾娟, 孙擎擎, 胡方方, 曹义娟, 祁玉娟. 子宫内膜容受性检测改善胚胎反复种植失败患者妊娠结局的临床应用[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 582-587.
[4] 周东杰, 蒋敏, 范海瑞, 高玲玲, 孔祥, 卢丹, 王丽萍. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 387-393.
[5] 韩春颖, 王婷婷, 李艳艳, 朴金霞. 子宫内膜癌患者淋巴管间隙浸润预测因素研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 403-409.
[6] 刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[7] 魏权, 张燊, 陈慧佳, 邹姮, 胡丽娜. 女性生殖道微生物群与辅助生殖技术相关性研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 151-155.
[8] 刘艳艳, 谭曦, 彭雪. 妊娠合并膀胱低度恶性潜能乳头状尿路上皮肿瘤并文献复习[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 212-218.
[9] 胡欧婵, 黄仲英. 不明原因复发性流产患者的治疗研究现状与展望[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 16-22.
[10] 田亚, 吴美龙, 冯晓彬. 人工智能在肝细胞癌诊疗中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(03): 258-262.
[11] 黄晴, 赵瑞珩, 钱惠英. PCI-24781诱导SKOV-3细胞凋亡及相关机制的研究[J]. 中华临床医师杂志(电子版), 2022, 16(08): 775-781.
[12] 刘育昕, 王子晗, 张艺馨, 栾永婕, 孟凯. 肾母细胞瘤基因1在卵巢疾病发病机制中的研究进展[J]. 中华诊断学电子杂志, 2023, 11(03): 178-183.
[13] 胡蓉, 李梅芳, 王磊, 贺艳杰, 李晓丹, 李玉华. 精准诊断在内科学血液肿瘤疾病理论教学中的应用[J]. 中华诊断学电子杂志, 2023, 11(01): 67-69.
[14] 王可珺, 李吉镇, 马标, 续慧超, 谌红珊, 刘雷. 肌酐/胱抑素C对晚期上皮性卵巢癌术后并发症的预测价值[J]. 中华诊断学电子杂志, 2023, 11(01): 49-55.
[15] 邵柏棕. 消化学科研究中的分子生物学实验方法教学与培训体会[J]. 中华胃肠内镜电子杂志, 2023, 10(01): 67-69.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号